cGMP in the vasculature.
Cyclic guanosine 3', 5'-monophosphate (cGMP) plays an integral role in the control of vascular function. Generated from guanylate cyclases in response to the endogenous ligands, nitric oxide (NO) and natriuretic peptides (NPs), cGMP influences a number of vascular cell types and regulates vasomotor tone, endothelial permeability, cell growth and differentiation, as well as platelet and blood cell interactions. Reciprocal regulation of the NO-cGMP and NP-cGMP pathways is evident in the vasculature such that one cGMP generating system may compensate for the dysfunction of the other. Indeed, aberrant cGMP production and/or signalling accompanies many vascular disorders such as hypertension, atherosclerosis, coronary artery disease and diabetic complications. This chapter highlights the main vascular functions of cGMP, its role in disease and the resulting current and potential therapeutic applications. With respect to pulmonary hypertension, heart failure and erectile dysfunction, as well as cGMP signal transduction, the reader is specifically referred to other dedicated chapters.
Kemp-Harper
Barbara
B
Department of Pharmacology, Monash University, Melbourne (Clayton), VIC, 3800, Australia. barbara.kemp@med.monash.edu.au
Schmidt
Harald H H W
HH
D000818:Animals; D002199:Capillary Permeability / Q000502:physiology; D006152:Cyclic GMP / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000502:physiology; D006801:Humans; D015398:Signal Transduction / Q000502:physiology*; D014652:Vascular Diseases / Q000503:physiopathology*
D006152:Cyclic GMP